Explore the gap between patient and clinician perspectives in psoriatic arthritis care. Learn how priorities differ and why ...
Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.
Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback